OMNIOME, INC.

Profile

Company Names

OMNIOME, INC.

Addresses

10275 SCIENCE CENTER DRIVE, SAN DIEGO, CA 92121

10575 ROSELLE STREET, SAN DIEGO, CA 92121

4225 EXECUTIVE SQUARE #480, SAN DIEGO, CA 92037

Phone Numbers

(858) 832-2300
(619) 796-2838

 

Entity Type:

CORPORATION

Industry:

BIOTECHNOLOGY

Year Incorporated:

2013

State Incorporated:

DELAWARE

Total Amount Raised:

$100,225,001.00

Number of Funding Rounds:

3
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
3
2019-11-27 
$60,000,003.00 
$60,000,003.00 
$0.00 
Equity 
2
2018-06-28 
$39,999,998.00 
$39,999,998.00 
$0.00 
Equity 
1
2014-05-15 
$225,000.00 
$1,000,000.00 
$775,000.00 
Debt 
People
First Name
Middle Name
Last Name
Titles
Related Companies
MILLARD 
Y 
CHAN 
EXECUTIVE OFFICER, DIRECTOR
OMNIOME, INC.
DAVID 
 
CRUIKSHANK 
DIRECTOR
PIXELEXX SYSTEMS, INC.   |  CYTRELLIS BIOSYSTEMS, INC.   |  OMNIOME, INC.   |  AGBIOME, LLC
KIM 
 
KAMDAR, PH.D. 
DIRECTOR
SYNDAX PHARMACEUTICALS INC   |  SALVEO DX, INC.   |  OBALON THERAPEUTICS INC   |  OMNIOME, INC.
CATHERINE 
 
LEE 
EXECUTIVE OFFICER
BERGAMOT SPECIAL SITUATIONS FUND I L.P.   |  ATP FUND 6 SOPHIE 2017, LP   |  ATP FUND 7 GIORGETTI 2017, LP   |  OMNIOME, INC.   |  TFF PHARMACEUTICALS, INC.
DAVID 
S. 
MULLARKEY 
EXECUTIVE OFFICER, DIRECTOR
OMNIOME, INC.
JOHN 
 
MURPHY, PH.D. 
EXECUTIVE OFFICER
OMNIOME, INC.
BORIS 
 
NIKOLIC, M.D. 
DIRECTOR
OMNIOME, INC.
ARNOLD 
 
OLIPHANT 
EXECUTIVE OFFICER
OMNIOME, INC.
KELLY 
 
PEREZ 
EXECUTIVE OFFICER
OMNIOME, INC.
KEN 
 
SONG, M.D., PH.D. 
EXECUTIVE OFFICER, DIRECTOR
OMNIOME, INC.
KANDASWAMY 
 
VIJAYAN 
EXECUTIVE OFFICER, DIRECTOR
OMNIOME, INC.   |  ZAFRENS INC.
MICHAEL 
 
YI 
DIRECTOR
GOSSAMER BIO, INC.   |  NEXTCURE, INC.   |  OMNIOME, INC.   |  BEAM THERAPEUTICS INC.   |  ALIGOS THERAPEUTICS, INC.
DAN 
 
ZABROWSKI 
DIRECTOR
OMNIOME, INC.   |  APEXIGEN, INC.   |  ACTUATE THERAPEUTICS, INC.   |  APEXIGEN, INC.
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2019-12-11
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2019-11-27 
2019-02-26
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2018-06-28 
2014-05-22
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Debt 
2014-05-15 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#
NONE
NONE
N/A
NONE